CC-1

N/A

Report date: 2026/03/19 16:52:39

Base Information

Drug NameCC-1

Drug Alias NamePSMAxCD3 bispecific antibodyCC-1

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionCD3 T-cell engagersProstate-Specific Membrane Antigen inhibitors

TargetsProstate-Specific Membrane AntigenT cell surface glycoprotein CD3

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesBiconY Therapeutics Gmbh

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Hospital Tuebingen

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A